GEN Exclusives

More »

GEN News Highlights

More »
Dec 17, 2010

Recordati Pays Nymox €10M Up Front for Rights to Late-Stage BPH Drug in 81 Countries

  • Recordati is paying Nymox Pharmaceuticals €10 million (about $13 million) up front for exclusive rights to develop and commercialize the latter’s Phase III-stage benign prostatic hyperplasia (BPH) drug NX-1207 in 81 countries within Europe (including Russia and the CIS), the Middle East, the Maghreb region of North Africa and South Africa.

    Nymox will in addition receive approval- and sales-related milestones along with tiered supply and royalty payments starting at 26% and increasing to 40% of total net sales if specific contractual conditions are met.

    Nymox is focused on the development of therapeutic and diagnostics targeting disorders that affect the ageing population. Lead product NX-1207 is currently undergoing pivotal Phase III trials in the U.S. The firm says completed Phase I and II trials have shown NX-1207 therapy improves the signs and symptoms of BPH, without the sexual, blood pressure, or other side effects associated with current treatments.

    NX-1207 is administered directly into the area of the enlarged prostate by a urologist in an office setting, without the need for anesthetic, sedation, or catheterization. In open-label follow-up studies a significant proportion of men receiving a single dose of NX-1207 have reported sustained improvements in BPH symptoms, without other treatments, for five years or longer, Nymox adds.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Tackling Climate Change

Do you think most companies will respond positively to the People’s Climate March?